RecruitingPhase 2NCT05571059
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Studying Idiopathic pulmonary fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cumberland Pharmaceuticals
- Principal Investigator
- Todd Rice, MD, MScCumberland Pharmaceuticals
- Intervention
- Ifetroban Sodium(drug)
- Enrollment
- 128 enrolled
- Eligibility
- 40 years · All sexes
- Timeline
- 2024 – 2027
Study locations (19)
- Biosolutions Clinical Research, La Mesa, California, United States
- University of California San Francisco, San Francisco, California, United States
- Mayo Clinic Jacksonville, Jacksonville, Florida, United States
- Miami VA Health System, Miami, Florida, United States
- Northwestern Medicine, Chicago, Illinois, United States
- Indiana University Health, Indianapolis, Indiana, United States
- University of Kansas, Kansas City, Kansas, United States
- University of Louisville, Louisville, Kentucky, United States
- Beaumont Hospital, Royal Oak, Royal Oak, Michigan, United States
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
- University of Rochester, Rochester, New York, United States
- UNC Chapel Hill, Chapel Hill, North Carolina, United States
- Bend Memorial Hospital, Bend, Oregon, United States
- Temple University Hospital, Philadelphia, Pennsylvania, United States
- Avera Research Institute, Sioux Falls, South Dakota, United States
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05571059 on ClinicalTrials.govOther trials for Idiopathic pulmonary fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05988463Dose-Escalation Study of Artesunate Patients With IPFJoseph C. Wu
- RECRUITINGNANCT07482917Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 TrialHospital de Granollers
- RECRUITINGNANCT07486206Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 TrialHospital de Granollers
- RECRUITINGPHASE2NCT06241560A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodBoehringer Ingelheim
- RECRUITINGPHASE3NCT07201922A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisBoehringer Ingelheim
- RECRUITINGNANCT07466420Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.Katerina M. Antoniou
- RECRUITINGPHASE3NCT07299695Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary FibrosisArgyrios Tzouvelekis
- RECRUITINGPHASE2NCT07284459Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary FibrosisContineum Therapeutics